NEW YORK–(BUSINESS WIRE)–Sofusa Holdings today announced its launch as an independent, clinical-stage company pioneering the development of a proprietary nanotechnology platform for precision targeting of lymphatic vessels and lymph nodes. The company has restarted manufacturing and plans to develop a pipeline of combination biologic products for autoimmune diseases, cancer and potentially other disorders of the immune system. In early human proof-of-concept clinical studies, the company’s Do